{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:09:47Z","timestamp":1788775787445,"version":"build-2803163510"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Everolimus, an mTOR inhibitor used in oncology and organ transplantation, requires therapeutic drug monitoring due to the narrow therapeutic range of everolimus and substantial pharmacokinetic variation. Patient-derived data can function as a supplementary quality indicator for laboratory methods by providing real-world information on analytical performance. Methods: All routine whole-blood everolimus measurements performed at Akademiska University Hospital, Uppsala, Sweden, 2012 to 2025 were retrospectively evaluated. In total, 9,089 results were included. Annual and monthly concentration distributions were assessed using the 10th, 25th, 50th, 75th, and 90th percentiles. Long-term trends, sex differences, seasonal variation, and the impact of a method change from Architect (Abbott\/Microgenics) to Cobas Pro e 801 (Roche) in 2021 were investigated. Results: Of 9089 results, 3335 were from females and 5754 from males. Concentration distributions were similar between sexes, with median concentrations of 4.47 and 4.33 \u00b5g\/L, respectively; the overall median was 4.37 \u00b5g\/L. Annual testing volumes remained stable. Median concentrations gradually declined from 5.22 \u00b5g\/L in 2012 to approximately 4.0 \u00b5g\/L in 2019\u20132020. Following introduction of the Cobas assay, patient concentration distributions shifted upward; compared with 2020, the 10th percentile increased by 45%, the median by 21%, and the 90th percentile by 11%. External quality assessment and method-comparison studies supported an analytical explanation. Conclusions: Everolimus concentration distributions were stable over time and showed no meaningful sex-related or seasonal variation. Patient percentile monitoring detected a clear analytical shift after method implementation and may serve as a practical supplementary quality indicator for TDM assays.<\/jats:p>","DOI":"10.3390\/ph19091412","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:23:37Z","timestamp":1788773017000},"page":"1412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Monitoring of Everolimus Concentrations in Routine Clinical Practice: Evaluation of Patient Percentiles as Quality Indicator and Impact of Analytical Method Change"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-0402","authenticated-orcid":false,"given":"Anders O.","family":"Larsson","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry and Pharmacology, Uppsala University, SE-751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-9575","authenticated-orcid":false,"given":"Anna-Karin","family":"Hamberg","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry and Pharmacology, Uppsala University, SE-751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-4210","authenticated-orcid":false,"given":"Mats B.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Anaesthesiology and Intensive Care, Uppsala University, SE-751 85 Uppsala, Sweden"},{"name":"NOVA Medical School, New University of Lisbon, 1169-056 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic Drug Monitoring of Everolimus: A Consensus Report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1592\/phco.30.10.1044","article-title":"Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology","volume":"30","author":"Gabardi","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0000000000001250","article-title":"Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"47","author":"Masuda","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000000376","article-title":"Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method","volume":"39","author":"Shipkova","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41397-020-0152-7","article-title":"Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients","volume":"20","author":"Bonnet","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trre.2017.02.007","article-title":"Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation","volume":"31","author":"Fischer","year":"2017","journal-title":"Transpl. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clinbiochem.2019.11.006","article-title":"An isotope dilution LC-MS\/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood","volume":"82","author":"Taibon","year":"2020","journal-title":"Clin. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-026-08012-5","article-title":"EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4\/6 inhibitor for ER-positive\/HER2-negative advanced breast cancer: EVERGREEN study","volume":"218","author":"Aftimos","year":"2026","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e70167","DOI":"10.1002\/ddr.70167","article-title":"Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights","volume":"86","author":"Hossain","year":"2025","journal-title":"Drug Dev. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"120009","DOI":"10.1016\/j.cca.2024.120009","article-title":"Transplant patient classification based on everolimus blood concentrations: Is there a risk of \u201cmisclassifications\u201d using immunoassays?","volume":"565","author":"Bargnoux","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aizawa, K., Kimura, N., Goda, T., Nishida, S., Sakuma, Y., Iwami, D., and Nagai, R. (2025). Analytical Validation of an LC-MS\/MS Method for Simultaneous Quantification of Multiple Immunosuppressants in Microvolume Whole Blood. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136358"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00440","DOI":"10.1016\/j.plabm.2024.e00440","article-title":"The measurement of immunosuppressive drugs bymass spectrometry and immunoassay in a SouthAfrican transplant setting","volume":"42","author":"Strydom","year":"2024","journal-title":"Pract. Lab Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/dmd.111.038125","article-title":"Seasonal variation in blood drug concentrations and a potential relationship to vitamin D","volume":"39","author":"Lindh","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1515\/cclm-2025-0163","article-title":"Improving the efficiency of quality control in clinical laboratory with an integrated PBRTQC system based on patient risk","volume":"63","author":"Duan","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1515\/cclm-2024-0041","article-title":"Sharing reference intervals and monitoring patients across laboratories\u2014Findings from a likely commutable external quality assurance program","volume":"62","author":"Farrell","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1373\/clinchem.2008.107052","article-title":"Traceability in laboratory medicine","volume":"55","author":"Vesper","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Larsson, A., Eriksson, M.B., Steinholtz, L., and Hamberg, A.K. (2026). Patient Median-Based Quality Control in Lamotrigine Therapeutic Drug Monitoring: A 15-Year Retrospective Study. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18020236"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Koo, S.E., Shim, S., Park, Y.H., Kang, E., and Park, H.D. (2026). Prospective real-time implementation and verification of patient-based real-time quality control using average of normals in a tertiary hospital laboratory. Clin. Chem. Lab. Med., Online ahead of print.","DOI":"10.1515\/cclm-2026-0201"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12944-025-02830-0","article-title":"A longitudinal analysis of population-level lipid and apolipoprotein trends over two decades: Descriptive assessment using patient medians in a Swedish tertiary care center","volume":"25","author":"Sejersen","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"120166","DOI":"10.1016\/j.cca.2025.120166","article-title":"Number of patient samples affected before error detection: Strategic implications for internal quality control and patient-based quality control practices","volume":"569","author":"Low","year":"2025","journal-title":"Clin. Chim. Acta"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:33:20Z","timestamp":1788773600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091412"],"URL":"https:\/\/doi.org\/10.3390\/ph19091412","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}